Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes

Journal of Clinical Oncology

Volumn 20, Issue 12, 2002, Pages 2805-2811

  Kaiser, Rolf ^a   Sezer, Orhan ^a   Papies, Anja ^a   Bauer, Steffen ^a   Schelenz, Claudia ^a   Tremblay, Pierre Benoit ^a   Possinger, Kurt ^a   Roots, Ivar ^a   Brockmölier, Jürgen ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DNA; GLUCOCORTICOID; ONDANSETRON; TROPISETRON;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ALLELE; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA AND VOMITING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP2D6; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDOLES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; ONDANSETRON; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0037096821     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.09.064     Document Type: Article

References (34)

1. Cancer therapy, vomiting, and antiemetics
2. The mechanism of emesis induced by anti-cancer therapies
3. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting
4. Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients
5. 3 receptor antagonist
6. Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy
7. 3 receptor antagonists
8. The area postrema and vomiting
9. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: A comparison of their pharmacology and clinical efficacy
10. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies
11. Plasma chromogranin A: A marker of serotonin release and of emesis associated with cisplatin chemotherapy
12. Cyclophosphamide increases 5-hydroxytryptamine release from the isolated ileum of the rat
13. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines - American Society of Clinical Oncology
14. 3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting
15. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron
16. 3 antagonists
17. Heterogeneity in systemic availability of ondansetron and granisetron following oral administration
18. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans
19. In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron
20. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron
21. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
22. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
23. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
24. Proposal for classifying the acute emetogenicity of cancer chemotherapy
25. Defining the emetogenicity of cancer chemotherapy regimens: Relevance to clinical practice
26. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis
27. Prevention of chemotherapy and radiotherapy -induced emesis: Results of Perugia consensus conference
28. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer
29. Guidelines for anti-emetic therapy: Acute emesis
30. Assuring the optimal use of serotonin antagonist antiemetics: The process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center
31. The influence of enzyme induction on polymorphic sparteine oxidation
32. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron
33. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: A quantitative systematic review of randomized placebo-controlled trials
34. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population